Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma

artículo científico publicado en 2019

AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis

scientific article published on 28 May 2019

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

artículo científico publicado en 2022

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

B cells and tertiary lymphoid structures promote immunotherapy response

artículo científico publicado en 2020

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

artículo científico publicado en 2015

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma

artículo científico publicado en 2014

Circulating Tumor Cells and Early Relapse in Node-positive Melanoma

artículo científico publicado en 2020

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial

artículo científico publicado en 2016

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients

artículo científico publicado en 2016

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity

scientific article published on 01 June 2020

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

scientific article published on 07 January 2021

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

scientific article published on 12 April 2022

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

scientific article published on 16 August 2018

Estrogen returns to the stage in melanoma

artículo científico publicado en 2018

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

artículo científico publicado en 2017

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

artículo científico publicado en 2017

In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma

scientific article published on 03 July 2019

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

artículo científico publicado en 2018

Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma

artículo científico publicado en 2020

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

artículo científico publicado en 2017

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

artículo científico publicado en 2015

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

scientific article published on 08 January 2020

Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition

artículo científico publicado en 2020

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

artículo científico publicado en 2015

Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

scientific article published on 11 September 2020

Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma

scientific article published on 19 May 2020

Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

artículo científico publicado en 2017

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases

artículo científico publicado en 2019

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker

artículo científico publicado en 2020

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

artículo científico publicado en 2016

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

artículo científico publicado en 2012

Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report

artículo científico publicado en 2020

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM).

artículo científico publicado en 2015

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features

artículo científico publicado en 2019

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

artículo científico publicado en 2018

Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma

artículo científico publicado en 2021

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

artículo científico publicado en 2020

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

artículo científico publicado en 2012

Targeted therapy strategies for melanoma brain metastasis

artículo científico publicado en 2021

Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs

scientific article published on 19 July 2018

The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression.

artículo científico publicado en 2018

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma

AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

B cells and tertiary lymphoid structures promote immunotherapy response

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma

Circulating Tumor Cells and Early Relapse in Node-positive Melanoma

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

Estrogen returns to the stage in melanoma

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma

Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM).

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

Targeted therapy strategies for melanoma brain metastasis

Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs

The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression.